Scribd Logo
Upload

Welcome to Scribd!

  • 8 views

    Biocon Grp5

    Uploaded by

    Abhishek Singh
    50% market share of BIOMAb Profit of BIOMAb is 32.5%(assuming 27.5% marketing costs) CAGR of cancer patients in India is 3.11% patients able to afford the drug 1% If price charged is $1000 / dose then break-even will be in 11. Years.

    Copyright:

    Attribution Non-Commercial (BY-NC)
    Download as PPTX, PDF, TXT or read online from Scribd
    Flag for inappropriate content

    You might also like

    Biocon Grp5

    Uploaded by

    Abhishek Singh
    8 views2 pages
    50% market share of BIOMAb Profit of BIOMAb is 32.5%(assuming 27.5% marketing costs) CAGR of cancer patients in India is 3.11% patients able to afford the drug 1% If price charged is $1000 / dose then break-even will be in 11. Years.

    Original Description:

    Copyright

    © Attribution Non-Commercial (BY-NC)

    Available Formats

    PPTX, PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Report this Document
    50% market share of BIOMAb Profit of BIOMAb is 32.5%(assuming 27.5% marketing costs) CAGR of cancer patients in India is 3.11% patients able to afford the drug 1% If price charged is $1000 / dose then break-even will be in 11. Years.

    Copyright:

    Attribution Non-Commercial (BY-NC)
    Download as PPTX, PDF, TXT or read online from Scribd
    Flag for inappropriate content
    Download as pptx, pdf, or txt
    8 views2 pages

    Biocon Grp5

    Uploaded by

    Abhishek Singh
    50% market share of BIOMAb Profit of BIOMAb is 32.5%(assuming 27.5% marketing costs) CAGR of cancer patients in India is 3.11% patients able to afford the drug 1% If price charged is $1000 / dose then break-even will be in 11. Years.

    Copyright:

    Attribution Non-Commercial (BY-NC)
    Download as PPTX, PDF, TXT or read online from Scribd
    Flag for inappropriate content
    Download as pptx, pdf, or txt
    of 2

    Analysis

    Assumption: 50% market share of BIOMAb Profit of BIOMAb is 32.5%(assuming 27.5%

    marketing costs) CAGR of cancer patients in India is 3.11% Patients able to afford the drug 1% If price charged is $1000/dose then break-even will be in 11.4 years If price charged is $2000/dose then break-even will be in 6.2 years If price charged is $1500/dose the n break-even will be in 8.1 years

    Analysis
    market potential(no of patients)
    2900
    2700 2500 2284 2355 2428

    2300
    2100 1900 1900 1959 2020 2083

    2148

    2215

    1700
    1500

    2007

    2008

    2009

    2010

    2011

    2012

    2013

    2014

    2015

    You might also like